Recro Pharma, Inc. (REPH)
(Delayed Data from NSDQ)
$9.00 USD
0.00 (0.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.99 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.00 USD
0.00 (0.00%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.99 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.
Recro Pharma (REPH) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Recro Pharma (REPH) has been struggling lately, but the selling pressure may be coming to an end soon.
Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Recro Pharma (REPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ironwood (IRWD) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Ironwood (IRWD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
All You Need to Know About Recro Pharma (REPH) Rating Upgrade to Buy
by Zacks Equity Research
Recro Pharma (REPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is the Options Market Predicting a Spike in Recro Pharma (REPH) Stock?
by Zacks Equity Research
Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.
Recro Pharma (REPH) in Focus: Stock Moves 7.6% Higher
by Zacks Equity Research
Recro Pharma (REPH) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Recro Pharma (REPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Recro Pharma (REPH) delivered earnings and revenue surprises of -46.15% and 27.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Recro Pharma (REPH) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Recro Pharma (REPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
Will Recro Pharma Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Recro Pharma.
Recro Pharma (REPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Recro Pharma (REPH) delivered earnings and revenue surprises of 63.89% and 29.90%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Recro Pharma (REPH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Recro Pharma (REPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst Pharma (CPRX) Rides on Successful Launch of Firdapse
by Zacks Equity Research
Catalyst Pharma (CPRX) gains on the successful launch of Firdapse. The company is looking to develop drug for additional indications.
Catalent Acquires Gene Therapy Leader Paragon Bioservices
by Zacks Equity Research
Catalent (CTLT) acquires gene therapy leader Paragon Bioservices for $1.2 billion.
New Strong Buy Stocks for May 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today
Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start
by Zacks Equity Research
Catalyst (CPRX) posts narrower-than-expected loss and beats on revenues in the first quarter of 2019.
Recro Pharma (REPH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Recro Pharma (REPH) delivered earnings and revenue surprises of 87.34% and 22.21%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.
Small Drug Stocks Outlook: Near-Term Prospects Encouraging
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaboration and M&A activity keep small drugmakers afloat in a competitive market.
Recro Pharma (REPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Recro Pharma (REPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recro Pharma, Inc. (REPH) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Recro Pharma, Inc. (REPH).
Recro Pharma Falls as FDA Denies Approval to Pain Candidate
by Zacks Equity Research
FDA issues complete response letter for Recro Pharma's (REPH) marketing application for pain candidate, meloxicam, for the second time.
Options Traders Expect Huge Moves in Recro Pharma (REPH) Stock
by Zacks Equity Research
Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.
What's in the Cards for Bausch Health (BHC) Q4 Earnings?
by Zacks Equity Research
Investors are looking forward to Salix and Bausch+Lomb's performance, and other pipeline updates when Bausch (BHC) reports Q4 results on Feb 20.